Mixed micropapillary-ductal carcinomas of the breast: A genomic and immunohistochemical analysis of morphologically distinct components

Journal of Pathology

Volumn 218, Issue 3, 2009, Pages 301-315

  Marchiò, Caterina ^a,b   Iravani, Marjan ^a   Natrajan, Rachael ^a   Lambros, Maryou B K ^a   Geyer, Felipe C ^a   Savage, Kay ^a   Parry, Suzanne ^a   Tamber, Narinder ^a   Fenwick, Kerry ^a   Mackay, Alan ^a   Schmitt, Fernando C ^c   Bussolati, Gianni ^b   Ellis, Ian ^d   Ashworth, Alan ^a   Sapino, Anna ^b   Reis Filho, Jorge S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF TURIN   (Italy)

^c University of Porto   (Portugal)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Breast cancer; Chromogenic in situ hybridization; Comparative genomic hybridization; Histological type; Microarray

Indexed keywords

CAVEOLIN 1; CYCLIN D1; CYTOKERATIN 14; CYTOKERATIN 17; CYTOKERATIN 5; CYTOKERATIN 6; DNA TOPOISOMERASE (ATP HYDROLYSING) A; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; UVOMORULIN;

ARTICLE; BREAST CARCINOMA; CANCER GRADING; CCND1 GENE; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; EGFR GENE; FGFR1 GENE; GENE AMPLIFICATION; GENETIC ANALYSIS; HER2 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MICROPAPILLARY CARCINOMA; ONCOGENE; ONCOGENE MYC; PRIORITY JOURNAL; TISSUE MICROARRAY; TOP2A GENE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, PAPILLARY; CHROMOSOME ABERRATIONS; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; HUMANS; IMMUNOPHENOTYPING; NEOPLASM PROTEINS; NEOPLASMS, COMPLEX AND MIXED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 67650073374     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2572     Document Type: Article

References (53)

1. Peterse JL. Breast carcinomas with an unexpected inside-out growth pattern. Rotation of polarisation associated with angioinvasion. Pathol Res Pract 1993;189:780 [abstr].
2. Ellis P, Schnitt SJ, Sastre-Garau X, Bussolati G, Tavassoli FA, Eusebi V, et al. Invasive breast carcinoma. In WHO Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs, Tavassoli FA, Devilee P (eds). JARC Press: Lyon, 2001.
3. Marchiò C, Iravani M, Natrajan R, Lambros MB, Savage K, Tamber N, et al. Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. J Pathol 2008;215:398- 410.
4. Thor AD, Eng C, Devries S, Paterakos M, Watkin WG, Edgerton S, et al. Invasive micropapillary carcinoma of the breast is associated with chromosome 8 abnormalities detected by comparative genomic hybridization. Hum Pathol 2002;33:628-631.
5. Weigelt B, Horlings H, Kreike B, Hayes M, Hauptmann M, Wessels L, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008;216:141-150.
6. Walsh MM, Bleiweiss IJ. Invasive micropapillary carcinoma of the breast: eighty cases of an underrecognized entity. Hum Pathol 2001;32:583-589.
7. Nassar H. Carcinomas with micropapillary morphology: clinical significance and current concepts. Adv Anat Pathol 2004;11:297- 303.
8. Amendoeira I, Magalhaes J, Damasceno M. Invasive micropapillary carcinoma of the breast: are the pure forms more aggressive than the mixed forms? Breast J 2003;9:337-338.
9. Chen L, Fan Y, Lang RG, Guo XJ, Sun YL, Cui LF, et al. Breast carcinoma with micropapillary features: clinicopathologic study and long-term follow-up of 100 cases. Int J Surg Pathol 2008;16:155-163.
10. Li YS, Kaneko M, Sakamoto DG, Takeshima Y, Inai K. The reversed apical pattern of MUC1 expression is characteristics of invasive micropapillary carcinoma of the breast. Breast Cancer 2006;13:58-63.
11. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-410.
12. Buerger H, Mommers EC, Littmann R, Simon R, Diallo R, Poremba C, et al. Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution. J Pathol 2001;194:165-170.
13. Buerger H, Otterbach F, Simon R, Poremba C, Diallo R, Decker T, et al. Comparative genomic hybridization of ductal carcinoma in situ of the breast - evidence of multiple genetic pathways. J Pathol 1999;187:396-402.
14. Loo LW, Grove DI, Williams EM, Neal CL, Cousens LA, Schubert EL, et al. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res 2004;64:8541-8549.
15. Pierga JY, Reis-Filho JS, Cleator SJ, Dexter T, Mackay A, Simpson P, et al. Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy. Br J Cancer 2007;96:341-351.
16. Rennstam K, Ahlstedt-Soini M, Baldetorp B, Bendahl PO, Borg A, Karhu R, et al. Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. Cancer Res 2003;63:8861-8868.
17. Roylance R, Gorman P, Harris W, Liebmann R, Barnes D, Hanby A, et al. Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res 1999;59:1433-1436.
18. Simpson PT, Gale T, Reis-Filho JS, Jones C, Parry S, Sloane JP, et al. Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. Am J Surg Pathol 2005;29:734-746.
19. Marchiò C, Natrajan R, Shiu K, Lambros M, Rodriguez-Pinilla S, Tan D, et al. The genomic profile of HER2-amplified breast cancers: the influence of ER status. J Pathol 2008;216:399-407.
20. Reis-Filho JS, Pinheiro C, Lambros MB, Milanezi F, Carvalho S, Savage K, et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol 2006;209:445-453.
21. van Beers EH, Joosse SA, Ligtenberg MJ, Fles R, Hogervorst FB, Verhoef S, et al. A multiplex PCR predictor for aCGH success of FFPE samples. Br J Cancer 2006;94:333-337.
22. Coe BP, Ylstra B, Carvalho B, Meijer GA, Macaulay C, Lam WL. Resolving the resolution of array CGH. Genomics 2007;89:647-653.
23. Gunnarsson R, Staaf J, Jansson M, Ottesen AM, Goransson H, Liljedahl U, et al. Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia - a comparative study of four differently designed, high resolution microarray platforms. Genes Chromosomes Cancer 2008;47:697-711.
24. Tan DS, Lambros MB, Natrajan R, Reis-Filho JS. Getting it right: designing microarray (and not 'microawry') comparative genomic hybridization studies for cancer research. Lab Invest 2007;87:737-754.
25. Arriola E, Lambros MB, Jones C, Dexter T, Mackay A, Tan DS, et al. Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation. Lab Invest 2007;87:75-83.
26. Natrajan R, Little SE, Sodha N, Reis-Filho JS, Mackay A, Fenwick K, et al. Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour. J Pathol 2007;211:52-59.
27. Simpson PT, Reis-Filho JS, Lambros MB, Jones C, Steele D, Mackay A, et al. Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. J Pathol 2008;215:231-244.
28. Reis-Filho JS, Simpson PT, Jones C, Steele D, Mackay A, Iravani M, et al. Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J Pathol 2005;207:1-13.
29. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-1481.
30. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Speci-ficity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999;17:1983-1987.
31. Reis-Filho JS, Savage K, Lambros MB, James M, Steele D, Jones RL, et al. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol 2006;19:999-1009.
32. Tan DS, Marchio C, Jones RL, Savage K, Smith IE, Dowsett M, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008;111:27-44.
33. Savage K, Lambros MB, Robertson D, Jones RL, Jones C, Mackay A, et al. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res 2007;13:90-101.
34. Mahler-Araujo B, Savage K, Parry S, Reis-Filho JS. Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype. J Clin Pathol 2008;61:615-620.
35. Arriola E, Rodriguez-Pinilla SM, Lambros MB, Jones RL, James M, Savage K, et al. Topoisomerase IIα amplification may predict benefit from adjuvant anthracyclines in HER2-positive early breast cancer. Breast Cancer Res Treat 2007;106:181-189.
36. Parry S, Savage K, Marchio C, Reis-Filho JS. Nestin is expressed in basal-like and triple negative breast cancers. J Clin Pathol 2008;61:1045-1050.
37. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-5374.
38. Elbauomy Elsheikh S, Green AR, Lambros MB, Turner NC, Grainge MJ, Powe D, et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res 2007;9:R23.
39. Reis-Filho JS, Simpson PT, Turner NC, Lambros MB, Jones C, Mackay A, et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 2006;12:6652-6662.
40. Lambros MB, Simpson PT, Jones C, Natrajan R, Westbury C, Steele D, et al. Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab Invest 2006;86:398-408.
41. Arriola E, Marchio C, Tan DS, Drury SC, Lambros MB, Natrajan R, et al. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest 2008;88:491-503.
42. Reis-Filho JS, Drury S, Lambros MB, Marchio C, Johnson N, Natrajan R, et al. ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 2008;40:809-810; author reply, 810-812.
43. Bergamaschi A, Kim YH, Wang P, Sorlie T, Hernandez-Boussard T, Lonning PE, et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 2006;45:1033-1040.
44. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006;10:529-541.
45. Hicks J, Krasnitz A, Lakshmi B, Navin NE, Riggs M, Leibu E, et al. Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res 2006;16:1465-1479.
46. Adelaide J, Finetti P, Bekhouche I, Repellini L, Geneix J, Sircoulomb F, et al. Integrated profiling of basal and luminal breast cancers. Cancer Res 2007;67:11565-11575.
47. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-527.
48. Reis-Filho J, Lakhani S. Breast cancer special types: why bother? J Pathol 2008;216:394-398.
49. Bernard-Pierrot I, Gruel N, Stransky N, Vincent-Salomon A, Reyal F, Raynal V, et al. Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer. Cancer Res 2008;68:7165-7175.
50. Araujo RW, Paiva V, Gartner F, Amendoeira I, Oliveira JM, Schmitt FC. Fine needle aspiration as a tool to establish primary human breast cancer cultures in vitro. Acta Cytol 1999;43:985-990.
51. Huang J, Gusnanto A, O'Sullivan K, Staaf J, Borg A, Pawitan Y. Robust smooth segmentation approach for array CGH data analysis. Bioinformatics 2007;23:2463-2469.
52. Hupe P, Stransky N, Thiery JP, Radvanyi F, Barillot E. Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics 2004;20:3413-3422.
53. Natrajan R, Williams RD, Hing SN, Mackay A, Reis-Filho JS, Fenwick K, et al. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse. J Pathol 2006;210:49-58.